Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Artivion (AORT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Artivion (AORT) over the last 16 years, with Q3 2025 value amounting to $39.0 million.

  • Artivion's Cost of Revenue rose 1214.55% to $39.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.1 million, marking a year-over-year increase of 991.39%. This contributed to the annual value of $139.8 million for FY2024, which is 1195.89% up from last year.
  • Per Artivion's latest filing, its Cost of Revenue stood at $39.0 million for Q3 2025, which was up 1214.55% from $39.9 million recorded in Q2 2025.
  • Artivion's 5-year Cost of Revenue high stood at $39.9 million for Q2 2025, and its period low was $23.2 million during Q1 2021.
  • Over the past 5 years, Artivion's median Cost of Revenue value was $31.2 million (recorded in 2023), while the average stood at $31.1 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 4336.45% in 2021, then surged by 174.88% in 2022.
  • Quarter analysis of 5 years shows Artivion's Cost of Revenue stood at $28.0 million in 2021, then grew by 1.75% to $28.5 million in 2022, then increased by 14.26% to $32.6 million in 2023, then rose by 9.92% to $35.8 million in 2024, then rose by 8.9% to $39.0 million in 2025.
  • Its Cost of Revenue stands at $39.0 million for Q3 2025, versus $39.9 million for Q2 2025 and $35.4 million for Q1 2025.